Search
Powered By HealthLine
Health Tools
 Neurology Health Center
 Understanding Multiple Sclerosis
 Fibromyalgia Basics
 Video: Alzheimer's Disease
 Migraine - What is it?
Featured Conditions
 Alzheimer's
 Chronic Pain
 Multiple Sclerosis
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Drug Combo Fights Brain Tumors

Ivanhoe Newswire


Related Encyclopedia
 border=
Amenorrhea
Amniocentesis
Amniocentesis and CVS
Ankylosing Spondylitis
More...

Related Healthscout Videos
 border=
Baby Steps: Fertility Findings
Tumor Detecting App: Medicine's Next Big Thing?
Powerful Combo Reducing Lymphedema
Fighting Breast Cancer on Your Lunch Break
More...

Related Animations
 border=
Breast Reduction
Breast Self-Exam Video
Erectile Dysfunction
Facelift
More...

Related Drug Information
 border=
Actonel
Cialis
Detrol LA
Diflucan
More...

Related News Articles
 border=
Prenatal Antipsychotic Drugs Linked to Motor Delays: Study
Coffee Drinking in Pregnancy Won't Lead to Sleepless Baby: Study
1 in 5 Pharmacies Hinders Teens' Access to 'Morning-After' Pill: Study
'Freezing' Secondary Breast Cancer Tumors Shows Promise
More...

(Ivanhoe Newswire) -- Researchers have found a life-extending drug combination for people with a deadly type of brain tumor called glioblastoma multiforme (GBM).

Researchers from Duke Universitys Preston Robert Tisch Brain Tumor Center in Durham, N.C., studied 35 patients who had a recurrence of GBM. Each patient had already received standard treatment. For the study, the patients received a combination of the drugs bevacizumab (commonly known as Avastin) and irinotecan (Campto), a standard chemo drug.

Text Continues Below



James J. Vredenburgh, M.D., from Duke, was quoted as saying, Historically, when GBM recurred, there had typically been very little else we could do. But results of this study reveal nearly half of the patients on the drug combo had no tumor progression after six months and nearly 80 percent were still alive after six months.

Researchers report, typically, about 75 percent of people treated with standard chemotherapy have disease progression after six months and less than 50 percent are alive after six months.

Dr. Vredenburgh was quoted as saying, We found that this drug combination could significantly improve outcomes for these people, who are typically given about three to six months to live. These results represent tremendous hope for these patients and their families.

Avastin works by inhibiting the blood supply to the tumor that would otherwise cause it to grow rapidly. It has been used successfully to treat several cancers, including colorectal and lung cancers.

Dr. Vredenburgh reports, We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently or they work together, with the bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy.

This article was reported by Ivanhoe.com, which offers Medical Alerts by e-mail every day of the week. To subscribe, click on: http://www.ivanhoe.com/newsalert/.

SOURCE: Journal of Clinical Oncology, Oct. 20, 2007




Last updated 10/19/2007

Related Links
 border=
From Healthscout's partner site on chronic pain, ChronicPainConnection.com
Find ways to get chronic pain relief!
Find a right treatment for your chronic pain
Join our community - your chronic pain support group.





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire